Canadian trade union Unifor said roughly 4,500 of its members have been temporarily laid off because of the GM strike so far.Autosread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Roku shares have more than quadrupled this year, but the stock has had some rocky days of late as more players jump into streaming.Technologyread more
Legal experts say that California, which has pledged to sue, has a strong case that the administration's move is unlawful.Politicsread more
A group of 23 states on Friday sued to undo the Trump administration's determination that federal law bars California from setting stiff tailpipe emission standards and...Transportationread more
U.S. officials, including Secretary of State Mike Pompeo, have accused Iran of orchestrating devastating strikes on Saudi oil installations over the weekend.Politicsread more
Rosengren was one of two central bank officials to vote against Wednesday's quarter-point rate reduction, and explained in a speech to the Stern School of Business at New York...Economyread more
Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Apple's iPhone 11 ships with a slow charger in the box, but it supports fast charging. So buy this cable and charger to get a 50 percent charge in 30 minutes.Technologyread more
The process will involve three 14-day operations involving $30 billion as well as continued overnight operations of at least $75 billion each.The Fedread more
Some businesses, mostly small to midsize companies, are providing workers with paid time off to join the global climate strike, while others are shutting down operations...Weather & Natural Disastersread more
Shares in Indivior plunged 40 percent on Friday after it said a U.S. court ruling could lead to a generic rival to its treatment for opioid addiction that generates 80 percent of the London-listed drug maker's revenues.
Indivior has said it would not be able to rely on patents to prevent Indian firm Dr.Reddy's from making and marketing a generic alternative to Suboxone Film unless the ruling by the Delaware District Court was reversed on appeal.
Suboxone Film had an average market share in the United States of 61 percent in 2016, the firm said in a statement. The treatment accounted for 80 percent of Indivior's total revenues last year, it added.
Shares in Indivior were down about 40 percent at 252 pence at 0832 GMT, after the ruling on patents for the treatment delivered by dissolvable film placed under the tongue rather than by tablet. The fall wipes out this year's share gains.
Indivior, spun off from Reckitt Benckiser in 2014, said it could not quantify the precise financial impact of generic alternatives to Suboxone Film on revenues but said it "could potentially result in a rapid and material loss of market share for Suboxone Film in the U.S."
Indivior said that if pharmacies could substitute Suboxone Film with a generic rival without direct consultation with the patient it could lead to the treatment losing up to 80 percent of its market share "within a matter of months".
Indivior said that as of Aug. 29 the U.S. Food and Drug Administration (FDA) had not announced any marketing authorisation to a generic Suboxone Film alternative.
"Indivior says it's hard to gauge the financial impact but its dominant market position could collapse in a matter of months," said Neil Wilson, senior market analyst at ETX capital.
Sales of Suboxone Film were higher in the first half of 2017 on the same period a year ago, but market share fell slightly to 59 percent from 61 percent. Generic rivals in tablet form are already on the market.
In September, 35 U.S. states and the District of Columbia filed a lawsuit against Indivior alleging that it tried to keep generic versions of a drug off the market.
The lawsuit by the states alleged that Indivior took steps to get patients to switch to the oral strip version of Suboxone.
Indivior said in its statement on Friday it would "continue vigorously defending its intellectual property."
Dr. Reddy's, whose shares were up 9 percent at 0832 GMT, bought the abbreviated new drug application (ANDA) for a generic rival treatment from Teva Pharmaceutical Industries in June 2016 for $70 million.
"Dr Reddy's still needs to obtain FDA approval. So even in the best case, launch by Dr. Reddy's is at least a year away," analysts at Credit Suisse wrote in a note.
Indivior said in June it had won a U.S. patent battle against Actavis and Par Pharmaceutical over Suboxone Film.